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Margaret L. MacMillan,1 Mark R. Hughes,2 Suneet Agarwal,3 George Q. Daley3Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hema-
tologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such
that transplant outcomes have markedly improved. With the development of in vitro fertilization and pre-
implantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option
for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach
to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous
stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors.
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Fanconi anemia (FA) is a genetically and pheno-
typically heterogeneous disorder characterized by
congenital malformations, progressive marrow fail-
ure, and a marked predisposition to malignancy [1].
Hematologic abnormalities occur in FA patients at
a median of 7 years (range: birth to 31 years) [2]. By
40 years of age, the risk of developing bone marrow
failure is 90%, advanced myelodysplastic syndrome
(MDS). or acute leukemia 33%, and nonhematologic
malignancies 28% [3]. To date, allogeneic hematopoi-
etic cell transplantation (HCT) remains the only
proven therapy to potentially cure the hematologic
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HCT for FA patients is uniquely challenging for
a number of reasons. FA patients are hypersensitive
to DNA alkylating agents [4,5] and irradiation [6],
and therefore can only tolerate substantially lower
doses of chemotherapy and radiation compared to
non-FA patients. In 1984, Gluckman [7] developed
the first successful preparative regimen for FA patients
consisting of low-dose cyclophosphamide (CY) and
single-fraction irradiation. This novel approach led
to a marked reduction in regimen-related toxicity
(RRT) and enhanced survival, particularly after
HLA-matched sibling donor HCT. Nevertheless,
high rates of graft failure, acute and chronic graft-
versus-host disease (aGVHD, cGVHD), and opportu-
nistic infections still led to significant morbidity and
mortality, especially after alternative (ie, an HLA-
mismatched related or unrelated) donor HCT.
In 1985, Gluckman et al. [8] reported on 48 FA pa-
tients who underwent alternative donorHCT between
1978 and 1994 and reported to the International Bone
Marrow Transplant Registry (IBMTR) database.
Probabilities of aGVHD and cGVHD were 51% and
46%, respectively. The probability of survival at 2
years was 29%. Notably, graft failure occurred in
24% patients, suggesting the reduced-intensity condi-
tioning was insufficient to eradicate host cells. In 2000,
MacMillan et al. [9] observed a particularly high rate of
graft failure in patients with T cell mosaicism, suggest-
ing that the presence of diepoxybutane (DEB)-
resistant T cells increased the risk of rejection. It was
hypothesized that the standard preparative therapy
consisting of CY, total-body irradiation (TBI), and an-
tithymocyte globulin (ATG) was insufficient to eradi-
cate DEB-resistant T cells [9]. Historically, high ratesS109
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uted to poor survival after alternative donor HCT
for FA patients.THE PRESENT
Many of the initial HCT obstacles have been over-
come in the last 2 decades translating into improved
survival rates. Most centers have added fludarabine
(FLU), an antimetabolite and immunosuppressive
agent, to the preparative regimen. As FLU is not
a crosslinking agent, it had the potential to enhance
immunosuppression and overcome the risk of graft
failure without increasing RRT. Additionally, the use
of T cell depletion (TCD) has greatly reduced the
risk of GVHD. This reduction of GVHD has not
only reduced the morbidity and mortality associated
with this complication, but potentially the risk for
late malignancies that have been linked to the develop-
ment of GVHD [10,11]. The major remaining HCT
goals are to decrease the risks for opportunistic
infections and for late complications including
malignancies, endocrinopathies, and sterility.
HLA-Identical Sibling Donor HCT
At present, HCT from HLA-identical sibling do-
nors is usually associated with an excellent outcome
if performed prior to the development of advanced
MDS or acute leukemia, particularly within the first
decade of life. Historically, the Gluckman approach
of low-dose CY and limited field irradiation (LFI)
has been the standard HCT preparative regimen [7].
Factors associated with higher survival after HLA-
identical sibling HCT have included age at transplant,
pretransplant platelet count, conditioning regimen,
and GVHD prophylaxis [8,12].
Over this past decade, a major focus has been the
elimination of irradiation from the preparative regimen
prior to HLA-identical sibling donor HCT as a means
to potentially reduce the risk of late malignancies. Sev-
eral centers have been successful by either increasing
the amount of CY [13,14], adding busulfan (BU) to CY
[15,16], or adding FLU to CY [16-19]. In 2008,
Pasquini et al. [20], on behalf of the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR) compared the early HCT outcomes using
nonirradiation containing regimens (n 5 71) to out-
comes of regimens with irradiation (n5 77) for FA pa-
tients transplanted with HLA-matched sibling donors.
Hematopoietic recovery, aGVHD, cGVHD, and sur-
vival were similar after the 2 types of regimens. With
a median follow-up of .5 years, the 5-year probability
of survival was 78% after irradiation-containing regi-
mens and 81%after nonirradiationcontaining regimens.
At the University of Minnesota, MacMillan et al.
[18] developed a nonirradiation-based regimen usinglow-dose CY (20 mg/kg), FLU (175 mg/m2), and
ATG (150 mg/kg) [18]. To date, 24 patients with FA
have undergone HLA-genotypic identical TCD bone
marrow (BM) or umbilical cord blood (UCB) HCT
using this regimen. All patients achieved neutrophil
engraftment, and none developed aGVHD or
cGVHD. Of the 22 FA patients with aplastic anemia
prior to HCT, 20 are alive and well. Longer follow-
up of these patients and others who received
chemotherapy-only-based regimens is necessary to
determine whether the elimination of irradiation has
reduced late effects particularly the development of
malignancies.Alternative Donor HCT
The majority of FA patients do not have an unaf-
fected (ie, FA negative) HLA-identical sibling donor.
Until recently, alternative donor HCT for patients
with FA was less successful than after HLA-identical
donors because of high rates of graft failure, GVHD,
and opportunistic infections. As with HLA-identical
sibling HCT, the addition of FLU to the preparative
regimen has greatly enhanced engraftment, and
TCD has markedly decreased the risk of GVHD after
alternative donor HCT. Factors associated with
improved survival after alternative donor HCT for
FA include younger age, good organ function, negative
cytomegalovirus (CMV) serostatus, adequate stem cell
dose, and good Karnofsky performance status
[9,21,22]. Poorer survival has been associated with
the number of malformations ($3 sites), prior
exposure to androgens and absence of FLU in the
preparative therapy [9,21,22].
In 2007, Wagner et al. [22], on behalf of the
CIBMTR, reported the results of 98 FA patients
who underwent unrelated donor BM transplantation
between 1990 and 2003. Nearly all recipients (44 of
36) of a FLU-based preparative regimen received
T cell-depleted grafts versus half (26 of 52) of the re-
cipients of non-FLU regimens. Probabilities of neu-
trophil recovery (89% versus 69%) and platelet
recovery (74% versus 23%) were higher after
FLU-containing regimens than non-FLU containing
regimens. Among recipients of non-FLU-containing
regimens, engraftment tended to be poorer in those
with evidence of DEB T cell mosaicism. Risk of
aGVHD was 4 times higher in recipients of unmanip-
ulated grafts compared to recipients of TCD grafts.
For recipients of a non-FLU-containing regimen,
the probability of grade II-IV aGVHD at day 100 after
HCT was 70% for non-TCD BM recipients and 21%
for TCD BM recipients. The probability of aGVHD
after a FLU-containing regimen was 16%. The use
of a FLU-containing regimen was also associated
with a higher probability of survival. Three-year
adjusted overall survival (OS) rates were 13% versus
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Other factors associated with higher survival were
younger recipient age (\10 years), CMV seronegativ-
ity in the recipient, and a history of fewer than 20 blood
product transfusions [22].
Similar to HLA-identical sibling HCT, efforts are
now underway to decrease or eliminate irradiation in
the conditioning regimen for alternative donor
HCT. A TBI dose deescalation trial was conducted
at the University of Minnesota to determine the lowest
dose of TBI required to achieve engraftment in FA pa-
tients undergoing alternative donor HCT [23]. All pa-
tients received CY 40 mg/kg, FLU 140 mg/m2, ATG
150 mg/kg, and a single fraction of TBI with CT
guided thymic shielding (TS, previously shown to
decrease the risk of opportunistic infections, possibly
by enhancing immune recovery [24]). TBI 300 cGy
with TS along with CY/FLU/ATG was determined
to be the lowest possible dose to achieve consistent
engraftment, whereas TBI 150 cGy with TS was not
adequate. Other centers have eliminated irradiation
by increasing the dose of CY. Long-term follow-up
studies are needed to determine whether these efforts
will lead to a lower rates of late malignancies.
HCT for FA patients with advanced MDS ($5%
blasts) or acute leukemia is more challenging. Al-
though there is some evidence that such patients can
tolerate chemotherapy prior to HCT [25], there is
no evidence it is necessary. Ideally FA patients are
monitored closely after diagnosis such that HCT oc-
curs before the development of advanced MDS or leu-
kemia. All FA patients should undergo a bone marrow
aspirate and biopsy with cytogenetic evaluation annu-
ally and more frequently if dysplastic changes or cyto-
genetic abnormalities are noted. FA patients should be
referred to a transplant center with an expertise in FA
prior to receiving transfusions to help facilitate a timely
HCT.In vitro Fertilization and Preimplantation
Genetic Diagnosis
Until recently, bone marrow was the preferred
stem cell source as further cells would be available in
the event of graft failure. However, as graft failure is
no longer a major obstacle, UCB is being utilized
more frequently as a stem cell source for patients
with FA [26]. Recently, in vitro fertilization and preim-
plantation genetic diagnosis (IVF-PGD) has been em-
ployed as a possiblemeans for parents of an affected FA
child to have an unaffected offspring [27]. In addition,
HLA screening can also be performed on the embryos
to identify potential HLA-matches to an already
affected child.
Couples undergo conventional IVF in their home
area as though they were infertile and 1 totipotent
blastomere is biopsied from each of their embryos onday 3 of development. The embryos are returned to
culture and the biopsy is couriered to a molecular ge-
netics reference center where the gene mutation(s) of
concern are analyzed and the HLA haplotypes are
determined overnight in 1 cell. The following day,
embryos found to be genetically unaffected and
HLA-identical to the affected child are transferred to
the uterus. Scientists at Genesis Genetics first began
performing this technology in 1998 for severe com-
bined immunodeficiency syndrome (SCID), and by
2000, PGD for disease and HLA had been expanded
successfully to include FA, Diamond Blackfan,
Schwachman Diamond, and Wiskott-Aldrich. Inter-
acting with some 230 fertility centers, Genesis Genet-
ics has successfully treated 154 couples for FA,
including 83 families for FANCA, 41 families for
FANCC, and 14 for FANCF.
Importantly, for IVF-PGD to be a possibility for
a couple to have an unaffected child, the specific muta-
tion of the affected child must be known in order to se-
lect nonaffected embryos. Chorionic villus sampling or
amniocentesis must be performed to confirm that the
fetus is healthy and HLA identical to the affected sib-
ling if desired. Prior to HCT, repeat testing is then
performed again once the UCB is collected.
It is imperative that couples contemplating IVF-
PGD have a team of experts to facilitate the process in-
cluding a PGD team, a transplant center, genetic
counselor, and an obstetrician. As IVF-PGD is
a time-consuming process, it can only be as an UCB
cell source if the affected sibling is stable enough to al-
low for sufficient time for the delivery of a healthy
HLA-identical sibling donor.THE FUTURE: INDUCED PLURIPOTENT
STEM CELLS
Stem Cell Models to Understand FA
Pathophysiology
In the past 15 years, 13 genes have been found to be
mutated in FA, and all appear to function in a common
pathway regulating DNA repair. However, the mech-
anism underlying bone marrow failure and hemato-
logic malignancy in patients with these mutations
remains largely unexplained. FA exemplifies many of
the difficulties with studying human genetic diseases
in mouse models or primary patient tissues. Cells
from patients with FA display a characteristic hyper-
sensitivity to DNA crosslinking agents such as mito-
mycin C, which is also evident in mice with deletions
in Fanca, Fancc, Fancg, and Fancd2. However, single
mutant mice do not developmarrow hypoplasia or leu-
kemia [28], but recent data shows that double mutants
in Fancc and Fancg reflect the marrow failure and mye-
lodysplasia seen in human disease, suggesting critical
differences between the functions of the mouse and
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mary hematopoietic cells from FA patients is restricted
by their limited numbers and poor proliferation, which
also hinders prospects for gene therapy. Pluripotent
stem cells offer a novel approach to model the hemato-
poietic developmental defects in FA, and as impor-
tantly, provide a potential source of patient-identical
stem cells that can be genetically manipulated and
used to generate corrected hematopoietic progenitors.
Human Embryonic Stem (ES) Cell Models of FA
ES cells are derived from blastocyst stage embryos
and possess several key attributes that make them
amenable to human disease modeling: (1) the ability
to divide and replicated endlessly (self-renewal); (2)
amenability to genetic manipulation (eg, gene knock-
down and gene targeting via homologous recombina-
tion); (3) and the ability to give rise to any tissue in
the body (pluripotency). To overcome the limitation
of obtaining hematopoietic progenitors from FA pa-
tients, Tulpule et al. [30] recently exploited ES cells
to model the effects of FA gene insufficiency on hema-
topoietic development in vitro. The authors depleted
FANCA and FANCD2 in human ES cells by stable
lentiviral-mediated RNA interference (RNAi), and
showed that the ES cells displayed the characteristic
DNA repair defects found in FA. FANCD2-depleted
ES cells showed a significant reduction in hematopoi-
etic gene expression and progenitors upon in vitro he-
matopoietic differentiation, whereas FANCA depleted
ES cells showed a similar but less severe phenotype.
The hematopoietic deficiencies in the knockdown
cell lines could be compensated by FA gene comple-
mentation. The results point to the importance of an
intact FA pathway in the earliest stages of hematopoi-
etic development, which are recapitulated in human
ES directed differentiation protocols, and provide
a new experimental platform to explore pathogenesis
in FA.
Direct Reprogramming and Induced
Pluripotency
ES cell modeling of human genetic diseases by
lentiviral knockdown is limited by difficulties reca-
pitulating hypomorphic and qualitatively (rather
than quantitatively) defective disease alleles. Direct
reprogramming technology offers the remarkable
opportunity to generate ES-like cells directly from pa-
tient tissue samples, which carry the patient’s naturally
occurring disease alleles on their own genetic back-
ground. Following the landmark report by Takahashi
and Yamanaka in 2006 [31], several groups showed
that ectopic expression of a combination of transcrip-
tion factors (eg, OCT4, SOX2, KLF4, MYC, NANOG,
and LIN28) in adult human somatic cells, followed
by culture under ES cell conditions, permitted theidentification and isolation of cells that had reverted
to an embryonic-like state, so-called induced pluripotent
stem (iPS) cells [32-34]. Human iPS technology thus
permits the creation of highly tractable and versatile
cell lines carrying our patients’ genetic lesions [35],
ushering in new possibilities for disease modeling and
autologous cellular therapy.Modeling FA Using iPS Technology
Several groups have attempted to generate iPS
cells from the somatic tissues of FA patients. As re-
cently reported by Raya et al. [36], however, reprog-
ramming primary fibroblasts from FA patients from
a variety of complementation groups has proven
extremely difficult. Rather, if the FA lesion is comple-
mented in the cells by introduction of a wild-type
transgene, reprogramming efficiency is restored and
iPS cells carrying the endogenous FA mutation can
be generated. Raya et al. [36] found that subsequent
knockdown of the correcting transgene led to rapid
loss of self-renewal. These results suggest, unexpect-
edly, that an intact FA pathway is required for induc-
tion and maintenance of pluripotency. Why might
this be? One possibility is that because cells carrying
FA mutations exhibit premature senescence, they are
unable to sustain sufficient cell divisions to undergo
reprogramming and/or they are unable to induce
self-renewal mechanisms while transitioning to a plu-
ripotent state. Moreover, conventional reprogram-
ming strategies such as those employed by Raya et al.
[36] depend on numerous retroviral or lentiviral
integration events. It is possible that disruption of
the DNA repair machinery in FA cells precludes reso-
lution of the DNA breaks associated with viral integra-
tion, resulting in cell death. Supporting this possibility
is a recent report by Mitalipov and colleagues [37] that
using nonintegrating transgenes for reprogramming
permits the generation of FA iPS cells without prior
correction of the underlying genetic lesion. These
iPS cells retained the characteristic FA-associated hy-
persensitivity to DNA crosslinking agents. However,
in contrast to the results of Raya et al. [36], these
disease-carrying FA cells can be propagated continu-
ously. Clearly, the FA-associated lesions hinder
reprogramming, but further studies will be required
to elucidate the precise role of the FA pathway in
induction and maintenance of pluripotency.
Like ES cells, human iPS cells have the potential
to be differentiated to any cell lineage in the body.
Importantly, Raya et al. [36] showed that transgene-
corrected FA iPS cells were able to give rise to hema-
topoietic progenitors by directed differentiation in
vitro. Given that hematopoietic stem cell failure is
a primary cause of death in FA, these studies set the
framework for gene correction in patient-identical
pluripotent stem cells, followed by derivation of
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Importantly, molecular analysis of blood progenitors
derived under current iPS differentiation protocols
suggests a primitive or embryonic phenotype, and it
is unclear what hematopoietic reconstitution potential
these derivatives possess. Generating definitive blood
progenitors from human ES and iPS cells that are
capable of long-term hematopoietic reconstitution is
an area of intense investigation [38].
Therapeutic Potential of iPS Cells for FA
and Other BM Failure Syndromes
iPS technology offers a potentially limitless source
of autologous, genetically tractable, tissue-specific
progenitors, which could circumvent the significant
complications of allogeneic HCT including RRT
and GVHD. We face several challenges on the road
to patient-specific iPS-based cellular therapy. First,
the original reprogramming strategies using retroviral
transgenes cause insertional mutagenesis, and reex-
pression of oncogenic factors such as MYC cause tu-
mors in iPS-derived mice [39]. Several strategies to
circumvent this problem have been reported, includ-
ing transient or nonintegrating DNA expression sys-
tems, transduction of proteins or RNA, and/or small
molecules [40-43]. Second, gene-targeting efficiency
is relatively poor in human pluripotent stem cells.
Tools such as zinc-finger nucleases and adeno-
associated viral vectors to increase homologous re-
combination efficiency [44,45], and methods to
convert human iPS cells to a more mouse-like plurip-
otent state [46], are being pursued to address this issue.
Third, and probably the most significant set of obsta-
cles facing the field, is how to derive definitive tissue
progenitors of interest from iPS cells, at a scale suitable
for human transplantation, and without partially
differentiated or undifferentiated cells in the final
transfusion/transplantation product. The genetic and
epigenetic integrity of the iPS derivatives will also
need to be ensured. Translating human iPS technol-
ogy to cellular therapy faces formidable challenges,
but if the recent history of the reprogramming field
is any indication, we may continue to expect the
unexpected.SUMMARY
Successful HCT for FA patients is challenging.
Many initial obstacles have been overcome, particu-
larly graft failure with the use of FLU, and GVHD
with the use of T cell depletion. The major remaining
HCT goals are to decrease the risks for opportunistic
infections, and for late complications including malig-
nancies, endocrinopathies, and sterility. With the
development of IVF-PGD, there is a greater opportu-
nity for parents to have further unaffected childrenwhomay also be an HLA-matched sibling donor for the
affected child. Patient-specific iPS-based cellular ther-
apy is being developed and may further reduce the
morbidity and mortality of HCT in the near future.ACKNOWLEDGMENTS
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